Review of Oral Triptans and Telcagepant for Migraine Treatment
Author Information
Author(s): Tfelt-Hansen Peer
Primary Institution: Department of Neurology, Danish Headache Center, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark
Hypothesis
What is the optimal balance of efficacy and tolerability for oral triptans and telcagepant in treating migraines?
Conclusion
A single 6 mg dose of subcutaneous sumatriptan is highly effective and well-tolerated for migraine attacks.
Supporting Evidence
- Subcutaneous sumatriptan 6 mg provides 81-91% headache relief at 2 hours.
- Oral triptans show a ceiling effect in efficacy, meaning higher doses do not increase effectiveness.
- Telcagepant has excellent tolerability with adverse events at placebo levels.
Takeaway
This study looks at different migraine medications and finds that some work really well but can also cause side effects. It's important to find the right dose that helps without making you feel bad.
Methodology
The study reviewed randomized controlled trials (RCTs) to analyze dose-response curves for efficacy and adverse events of triptans and telcagepant.
Potential Biases
Potential bias in reporting adverse events and efficacy due to the nature of the studies reviewed.
Limitations
The study primarily focuses on the efficacy and tolerability of specific doses without addressing long-term effects or individual variability in response.
Participant Demographics
The study does not provide specific demographic details about participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website